Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab sputum analysis in asthma
NCT02658877Phase 4Terminated
- Sponsor
- NYU Langone Health
- Start
- Jan 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in asthma, sponsored by NYU Langone Health. Started Jan 2016; status: terminated.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02658877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658877.